• Synthetic Biologics Inc (NYSE: SYN) has announced safety data from its Phase 1 multiple ascending dose (MAD) trial of SYN-020 intestinal alkaline phosphatase (IAP).

• The Phase 1 MAD study enrolled 32 healthy adult volunteers into four cohorts with SYN-020 administered orally in doses ranging from 5 mg to 75 mg twice daily for 14 days, with a follow-up evaluation at day 35.

• SYN-020 is a recombinant bovine IAP formulated for oral delivery to the small intestine and designed to diminish fat absorption and intestinal inflammation.

• Analyses of preliminary data demonstrated that SYN-020 maintained a favorable safety profile and was well-tolerated across all dose levels.

• There were a few treatment-related adverse events, and all were mild and resolved without medical intervention.

• The most common adverse event, constipation, occurred in three out of 24 subjects in the treatment arm and one out of eight subjects in the placebo arm.

• Additional analyses, including fecal levels of SYN-020 and anti-drug antibody levels, are ongoing.

• Price Action: SYN shares are up 0.18% at $0.23 on the last check Tuesday.

See more from Benzinga

• The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.